Patients with preoperatively suspected supratentorial meningiomas on imaging, whose lesions are adjacent to the precentral gyrus
Conditions
Interventions
Experimental group:In addition to the standard clinical management pathway, preoperative motor mapping was performed using helium-free MEG. During surgery, the OPM-MEG motor mapping results were integ
Control Group:Prior to surgery, participants underwent relevant examinations in accordance with standard clinical protocols (which may include fMRI, DTI, etc.). During surgery, routine imaging data we
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18–75 years; gender is not a factor; (2) Patients with a presumptive preoperative imaging diagnosis of supratentorial meningioma who are scheduled to undergo neurosurgical treatment; (3) The tumor’s area of abnormal signal on MRI contrast-enhanced imaging covers or compresses the precentral gyrus or paracentral lobule; (4) Patients who are able to understand and cooperate with this study and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with preoperative limb muscle strength below Grade 3 on the MRC muscle strength scale; (2) Patients with incomplete clinical data; (3) Patients with claustrophobia; (4) Patients unable to lie supine for more than 30 minutes; (5) Patients with ferromagnetic objects implanted above the costal margin of the thoracic cavity (internal foreign bodies, implanted pacemakers, cardiac resynchronization devices/defibrillators, infusion pumps, and/or nerve stimulators); (6) Patients with a confirmed diagnosis of psychiatric or psychological disorders, or those with uncontrolled psychiatric symptoms, who are unable to understand and cooperate with the study; (7) Patients with marked increased intracranial pressure, cerebral herniation, unstable vital signs, or meningioma suspected to be associated with tumor-related stroke; (8) Other conditions deemed by the investigator to render a patient ineligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of new-onset motor dysfunction assessed at the 3-month postoperative follow-up; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of motor dysfunction 7 days postoperatively;Incidence of severe motor dysfunction at 7 days and 3 months postoperatively;Consistency Between MEG Localization and Direct Cortical Stimulation (DCS) Localization;Extent of Tumor Resection (EOR);Incidence of Adverse Events/Serious Adverse Events;Incidence of Device-Related Discomfort;Device Defects; | — |
Countries
China
Contacts
Public ContactJi Nan
Beijing Tiantan Hospital, Capital Medical University
Outcome results
None listed